Research Article |
Corresponding author: Sally Ayad Almudaris ( sallymudaris@gmail.com ) Academic editor: Magdalena Kondeva-Burdina
© 2024 Sally Ayad Almudaris, Fouad Kadhim Gatea.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Almudaris SA, Gatea FK (2024) Effects of topical Ivermectin on imiquimod-induced Psoriasis in mouse model – Novel findings. Pharmacia 71: 1-14. https://doi.org/10.3897/pharmacia.71.e114753
|
Aim: investigate the possible anti-psoriatic effect of ivermectin in mice based on observational and histopathological outcomes and biomarkers.
Methods: Sixty male Swiss Albino Mice were divided into six groups (Groups I–VI); each group contained ten mice with shaved dorsal skin. The clinical, pathological, and laboratory effects were measured.
Results: Topical Ivermectin significantly decreased vascular endothelial growth factor levels. At the same time, the combination of ivermectin plus Clobetasol showed a more significant reduction in tumor necrosis factor-alpha (TNF-α) and Interleukin-17 (IL-17) levels. Regarding the Interleukin-10 (IL-10) level, the Ivermectin and Ivermectin/Clobetasol combination groups showed a significant increase in IL-10.
Conclusion: Topical Ivermectin’s anti-psoriasis activity increases IL-10 levels and could be used efficiently to alleviate psoriatic symptoms. Its combination treatment with Clobetasol holds promise for the management of psoriasis.
ivermectin, IL-10, TNF-a, VEGF, iL-17, psoriasis, imiquimod, histopathological study
Psoriasis is an immune-mediated inflammatory disease with a chronic prolapsing nature. Many factors can provoke psoriasis; some are genetic or external, like mild trauma, infection and sunburns, stress, and systemic drugs (
Psoriasis is generally classified into pustular and non-pustular psoriasis (such as psoriasis vulgaris, guttate psoriasis, inverse psoriasis, and erythrodermic psoriasis), and all the types share some common characteristics like erythema and thickening of the skin (
Dermatological application of Imiquimod (IMQ) – which is a Toll-like receptor (TLR) 7/8 ligand, induces and possibly exacerbates psoriasis; in a treated mouse model, it exhibits similarities to human plaque-type psoriasis in terms of skin erythema, thickening, scaling, epidermal alterations (acanthosis, parakeratosis), neo-angiogenesis, and inflammatory infiltrate comprising T cells, neutrophils, and dendritic cells (
Treatment of psoriasis usually focuses on treating the symptoms; there are different treatment options available for psoriasis, but none are curative, depending on the type, location, and severity of the lesions. Treatment may be topical, phototherapy, systemic, or a combination, depending on the disease severity (
Ivermectin (IVM) originates from a group of natural macrocyclic lactones known as avermectins, and it was originally isolated from the soil actinomycete Streptomyces avermectinius (
Ivermectin is a powerful angiogenesis inhibitor that can also inhibit proliferation and induce apoptosis in cells (
In this study, the main objective is to investigate the effect of topical ivermectin as a novel approach to treating psoriasis using the IMQ-induced mouse model. This model can assess ivermectin’s therapeutic potential in addressing psoriasis’s key pathological features, such as epidermal hyperplasia, inflammatory cell infiltration, and altered cytokine profiles. In addition to investigating the therapeutic effect of ivermectin/clobetasol combination on IMQ-induced mice model of psoriasis.
Male (Swiss Albino mice) weighing 28–32 g aged 2–3 months were randomly divided into six groups of 10 animals (60 mice). The animals were identified by marking different parts of the body. The mice were obtained from the (Animal Facility of the Al-Nahrain University – Biotechnology Research Center, Baghdad, Iraq), housed in polypropylene cages under a temperature-controlled environment (25 °C), with an inverted light-dark cycle (12/12 hours) and acclimated for seven days before starting the Experiment at the same center where the mice were obtained (Animal Facility of the Al-Nahrain University – Biotechnology research center, Baghdad, Iraq). The animals were maintained on a standard pellet diet and free access to water ad libitum supplied by Al-Nahrain University – Biotechnology Research Center. Before starting the Experiment, the animals were examined for the presence of any skin lesions, and only mice with apparently healthy skin and coat were included in the study; all animals that were included in the study underwent shaving from the dorsal region to expose an area of the back skin that measures about 1 × 2 cm for experimental purposes using an electric razor, followed by the application of a hair removal cream (Veet®, Reckitt Benckiser Pvt. Ltd., India), the remaining hair was then wiped away using gauze.
The total duration of the Experiment was 14 days from the starting day. Regarding the allocation of mice: Group I (Positive Control) consisted of 10 mice (n = 10) that remained as a control group with no intervention during the experimental duration. Group II (Psoriatic Control) consisted of 10 mice (n = 10) that received Induction of psoriasis by a dose of 62.5 mg of Imiquimod cream 5% as a once-daily topical application on the shaved back skin for six days duration until the appearance of a psoriatic lesion as mentioned by van der Fits et al. study (
Imiquimod cream was supplied as (Aldara® 5% Cream, Meda Pharmaceuticals, Solna, Sweden), Petrolatum Gel 15% was supplied from the local market (Iraqi Federation of Industries, Baghdad, Iraq), Clobetasol propionate was supplied as ointment preparation (Dermovate®, GlaxoSmithKline, Brentford, UK), and ivermectin was supplied as powder by (Hyperchem, Batch no. C1105113, Hangzhou, China) and later prepared as an ointment.
Induction of Psoriasis was done by using Imiquimod cream 5% as a once-daily topical application on the shaved back skin for six days until the appearance of a psoriatic lesion (
The PASI clinical scoring system was employed to examine the intensity of the inflammation of the mouse dorsal skin as a part of the assessment of induction models’ success and treatment efficacy in this study. It involved a visual evaluation of three characteristics on the back skin of each mouse, which are erythema (redness), induration (thickness), and desquamation (scale). Each characteristic was assigned a number between 0 and 4 (0 = None, 1 = Slight, 2 = Moderate, 3 = Marked, 4 = Very marked), resulting in a total score ranging from 0 to 12 (
Ivermectin, 1% ointment, was prepared according to the available concentration in the market that is approved by the
Commercial clobetasol ointment (Dermovate®) containing 0.05% clobetasole propionate (CP) was used with the prepared Ivermectin 1% ointment. An equal amount of both ivermectin and clobetasol (half concentration of both) was taken and well mixed by a spatula to obtain the final concentration of 0.5% Ivermectin and 0.025% clobetasol combination ointment (
The end of day 14 marked the end of the experimental period, and the outcome evaluation was done the next day. The evaluation of the treatment efficacy on the tested groups was based on the PASI Score (
After calculating the PASI score, all mice were anesthetized intraperitoneally (IP) with 80 mg/kg of ketamine and 10 mg/kg of xylazine. Following total anesthesia, all mice were terminated by exsanguination (cardiac puncture), a procedure suitable for tissue harvest and conservation (
Tissue samples were harvested from the dorsal shaved skin (1 cm) and divided into two pieces. The first piece was prepared for histopathological analysis by dehydration and immersion in liquid paraffin at a 55–60 °C temperature range. The slide was then prepared based on this method discussed by previous studies (
The second piece of skin tissue was prepared for biochemical analysis to measure the essay of Tumor Necrosis Factor-alpha (TNF-α), Interleukin 17 (IL-17), Interleukin 10 (IL-10), and Vascular Endothelial Growth Factor (VEGF), the preparation was done by rinsing the tissue in ice-cold Phosphate Buffered Saline (PBS) to remove excess blood thoroughly and weighed before homogenization, and then mincing it to small pieces and homogenization was done in fresh lysis buffer where 1 mL of lysis buffer is added to the tissue sample with a glass homogenizer on ice all by using the homogenizer machine (Electrical tissue homogenizer, Staruar®, England.). Then, the homogenates were centrifuged for 5 minutes at 10,000 RPM. The supernates were collected and stored at ≤ -20 °C until used for analysis by sandwich ELISA technique.
A histopathological grading system is used in determining the severity of inflammation (
The tissue morphology was imaged by the light microscope (Olympus BX51 Microscope, Olympus Corporation®, Japan), and five zones of a slide corner and the center were randomly viewed.
The stored samples were thawed and used for the analysis by sandwich Enzyme-Linked immunosorbent assay (ELISA) technique using the ELISA Reader (ELISA reader, Diagnostic Automation / Cortez Diagnostics®, California, USA). Regarding the ELISA kits, TNF-α was determined using the mice analytic kit (SCA133Mu, Cloud-Clone Corp.), IL-10 was determined using the mice analytic kit (SEA056Mu, Cloud-Clone Corp.), IL-17 was determined by the mice analytic kit (HEA063Mu, Cloud-Clone Corp.), and VEGF was determined using the mice analytical kit (SEA143Mu, Cloud-Clone Corp.).
For sample size computation, program G Power was utilized (
Data entry and analysis were performed using Microsoft Excel 2010 and SPSS version 26. Categorical variables were presented as frequencies and percentages using the Chi-square test. Test of Normality (Shapiro-Wilk) for continuous variables showed that data was non-normally distributed; thus, nonparametric tests (Mann Whitney) were used. Statistical analysis of different parameters in this study was expressed as mean ± standard deviation and P- values were significant when (P < 0.05) or highly significant when (P < 0.001) (
On day 4–5 of starting the Experiment, signs of psoriasis induction on mice skin, such as erythema, skin thickening, and scaling, began to show on the skin treated with IMQ and continued in the severity until the last day of Induction as shown in the figure below (Fig.
Scoring for skin inflammation severity, the pictures show different inflammation levels of the dorsal skin on which the test substances were applied on day 8 of the Experiment. A. Represents the healthy group; B. Represents the IMQ-induced group; C. Represents the vehicle group; D. Represents Clobetasol treated group; E. Represents the Ivermectin treated group; F. Represents Ivermectin + Clobetasol treated group.
Then, the mice were treated with petrolatum (group III), topical Clobetasol (group IV), ivermectin (group V), and a combination of ivermectin with Clobetasol (group VI), as shown in Fig.
The skin of experimental mice was observed for change during all days of the Experiment, and skin condition scoring was based on the PASI scoring system. In the healthy group, where nothing was applied to the skin, there were no signs of erythema, the skin is pink and healthy, and no signs of thickening or scaling appeared.
While on the skin treated with IMQ, the skin shows an increase in redness and inflammation from day three and an increase in severity along the Experiment days. There is also an increase in skin wrinkling and thickness, and scales begin to appear as yellow spots on the skin that advance to large, flaky scales on the last day of Induction.
The vehicle group showed no major changes in the skin after application, and there was only a slight reduction in skin scaling. At the same time, there were significant changes in skin appearance when Clobetasol and Ivermectin were applied. In the Clobetasol-treated group, there was a marked reduction in the skin erythema and the scaling of the skin surface; there was also a reduction in skin thickness noted as a decrease in the skin puckering and wrinkling in the induced areas. This improvement continued until the last day of the Experiment. However, in the group treated with ivermectin, there was a slight decrease in skin redness thickness and a marked reduction of scaling that started after three days of Ivermectin application. The combination group showed a marked reduction in skin erythema, thickness, and scaling, which started 2–3 days upon treatment application and continued until the last day of the Experiment.
The histopathologic section of healthy groups of skin mice showed normal epidermal, dermal, and subcutaneous tissue layers. In 4×, 10× in (H&E) stain, see Fig.
In the histopathological section of Induction, a group of skin mice showed a multifocal (wide) area of sloughing, severe dense neutrophilic infiltration (the Munro’s abscesses), and parakeratosis, hyperkeratosis, with lack of granular layer, acanthosis, increased rete ridges with papillary thinning. The dermis showed severe lymphocytic infiltration and vascular congestion. In 4×, 10×, and 40× H&E stain, see Fig.
Histopathological section of mice skin (induction group) showing hyperkeratosis, parakeratosis (black arrow), with multifocal dense neutrophilic infiltration (the Munro’s abscess) in red arrow, with epidermal acanthosis and thinning papillae and rete ridges appearance (green arrow), and lack of granular layer. The dermis shows moderate to severe inflammatory lymphocytic infiltration (blue arrow). H&E stain (4×,10×, 40×).
The histopathological skin of the induced vehicle group also showed epidermal hyperkeratosis and parakeratosis with focal Munro’s abscesses with acanthosis and elongated rete ridges and papillary thinning with moderate to severe lymphocytic infiltration. In 10× H&E stain, see Fig.
Histopathological section of mice skin (vehicle group) showing hyperkeratosis, parakeratosis (black arrow), with focal neutrophilic infiltration (the Munro’s abscess) in red arrow, with epidermal acanthosis and thinning papillae and elongated rete ridges (green arrow), and lack of granular layer. The dermis shows moderate to severe inflammatory lymphocytic infiltration (blue arrow). H&E stain (4×,10×).
The histopathological section of the standard treatment group (Clobetasol) mice skin shows hyperkeratosis, absence of parakeratosis & Munro’s abscess. And epidermal granular layer with mild acanthosis, few rete ridges with mild thinning of papillae with mild lymphocytic infiltration of the dermis. In 4×, 10× H&E stain, see Fig.
Histopathological section of mice skin (clobetasol control group) showing hyperkeratosis (black arrow), absence of parakeratosis & Munro’s abscess. And epidermal granular layer (yellow arrow) with mild acanthosis, mild papillary thinning, and few rete ridges (green arrow). The dermis shows mild lymphocytic infiltrate. H&E stain (4×,10×).
As for animals treated with ivermectin, the skin showed mild keratosis without Munro’s abscess and parakeratosis and epidermal mild acanthosis with few rete ridges and mild papillary thinning. The dermis was showing severe lymphocytic infiltrate. H&E stain (4×, 10×, 40×), see Fig.
Histopathological section of mice skin (Ivermectin treatment group) showing mild keratosis (black arrow), with the absence of Munro’s abscess and parakeratosis and epidermal mild acanthosis with few rete ridges and mild papillary thinning (green arrow). The dermis shows severe lymphocytic infiltrate. H&E stain (4×,10×, 40×).
The histopathological section of mice skin in the combination treatment group showed focal hyperkeratosis, mild epidermal thickness, with the absence of Munro’s abscess and parakeratosis and epidermal mild acanthosis with the absence of rete ridges & mild papillary thinning, and few chronic lymphocytic dermal infiltrations. In 4×, 10× H&E stain, see Fig.
Histopathological section of mice skin (Ivermectin treatment group) showing mild keratosis (black arrow), with the absence of Munro’s abscess and parakeratosis and epidermal mild acanthosis with few rete ridges and mild papillary thinning (green arrow). The dermis shows severe lymphocytic infiltrate. H&E stain (4×,10×).
This study included six groups, six mice in each group; these groups were healthy Control, induced non-treated, Petrolatum group, induced treated with Clobetasol group, induced treated with Ivermectin group, and induced treated with Ivermectin - Clobetasol group.
Comparison among the studied groups was made in the levels of tissue biomarkers (IL-10, IL-17, TNF-a, and VEGF), histopathological scores (Baker score), and observational scores (PASI score).
Tissue homogenate levels of tissue biomarkers (IL-17, TNF-a, and VEGF), histopathological scores (Baker score), and observational score (PASI score) were significantly highly increased, in addition, tissue homogenate level of IL-10 was significantly highly decreased among the induced non treated group after Induction in Comparison with the healthy control group, (P < 0.001)—Table
Comparison between the healthy control group and non-treated induced group regarding tissue biomarkers.
Parameters | Healthy Control Mean±SD | Induction group Mean±SD | p-value |
---|---|---|---|
IL-10 (pg/ml) | 286.26±63.80 | 31.83±3.03 | <0.001* |
IL-17 (pg/ml) | 222.41±64.33 | 553.04±141.32 | <0.001* |
TNF-a (ng/L) | 83.46±6.02 | 807.13±500.06 | <0.001* |
VEGF (pg/ml) | 120.99±15.83 | 552.20±136.63 | <0.001* |
Baker score | 0.50±0.00 | 9.00±0.00 | <0.001* |
PASI score | 0.00±0.00 | 11.70±0.48 | <0.001* |
Tissue homogenate levels of tissue biomarkers (IL-17, TNF-a, and VEGF), histopathological scores (Baker score), and observational score (PASI score) were significantly decreased; in addition, tissue homogenate level of IL-10 was significantly increased among Petrolatum group in Comparison with induced non treated group, (P < 0.05), as illustrated in Table
Comparison between the induced non-treated group and Petrolatum group regarding tissue biomarkers (IL-10, IL-17, TNF-a, and VEGF); histopathological scores (Baker score) and observational score (PASI score).
Parameters | Induction group Mean±SD | Petrolatum group Mean±SD | p-value |
---|---|---|---|
IL-10 (pg/ml) | 31.83±3.03 | 92.50±27.13 | <0.001* |
IL-17 (pg/ml) | 553.04±141.32 | 278.52±100.27 | <0.001* |
TNF-a (ng/L) | 807.13±500.06 | 281.79±240.17 | 0.008* |
VEGF (pg/ml) | 552.20±136.63 | 209.56±73.31 | <0.001* |
Baker score | 9.00±0.00 | 7.60±0.84 | 0.001* |
PASI score | 11.70±0.48 | 9.30±0.67 | <0.001* |
The data obtained has revealed a highly significant reduction in the tissue homogenate levels of tissue biomarkers (IL-17, TNF-a, and VEGF), in addition to a highly significant elevation in the tissue homogenate level of (IL-10) among all treated groups as compared with induction group (P < 0.05). Regarding IL-10 level, in comparison to the induction group, both Ivermectin and Ivermectin combination groups showed a significant elevation in IL-10 level P < 0.05, while ivermectin being more significant when compared with (Ivermectin-Clobetasol group). Regarding IL-17 level, it was significantly decreased among the Clobetasol group in Comparison to other treated groups; P < 0.001. Regarding TNF-a level, it was significantly decreased among the Ivermectin–Clobetasol group in Comparison to other treated groups; P < 0.05. The VEGF level was significantly lower among the Ivermectin group compared to the Clobetasol group and the Ivermectin-Clobetasol group; P < 0.05, as illustrated in Fig.
The data obtained has revealed a highly significant reduction in the histopathological scores (Baker score) and observational score (PASI score) among all treated groups as compared with the induction group (P < 0.05). Regarding Baker score, the lowest reduction in Baker score compared to the clobetasol group was shown among the Ivermectin group in Comparison to the ivermectin – clobetasol group with a high significant difference; P < 0.001. Regarding the PASI score, a highly significant reduction was shown among the clobetasol group, and the combination group was more significant than the Ivermectin group P < 0.001, as illustrated by Fig.
Petrolatum is defined as being an oleaginous semisolid, which is one of the commonly used treatment forms as topical formulations, as the oleaginous ointments are less irritant and have superior usability due to their texture and longer adhesion time than other formulas. One of the other advantages they possess is that they display superior skin protection effects, which are well absorbed through the skin and aid in the absorption of incorporated active ingredients in the ointment (
This study also investigated ivermectin’s topical effect on the mouse psoriasis model. It established IMQ-induced psoriasis and found that ivermectin ameliorated the histopathological changes, inflammatory cell infiltration, and keratinocyte hyper-proliferation.
After IMQ application, the development of psoriasis characteristic signs such as erythema, scaling, skin thickening, and hyperkeratosis, as seen in (Fig.
In this study, the results obtained from IMQ-induced psoriasis showed a significant reduction of the total PASI score of mice after treatment with Ivermectin topical preparation compared with the induced group and vehicle group, which achieved by a reduction in epidermal thickness and scaling, redness, however, took a longer time to disappear This might also be because of the hair removal cream application which caused a visible irritation and redness on the mice skin shortly upon application (
In addition, for the histological result, ivermectin showed mild keratosis, with the absence of Munro’s abscess and parakeratosis and epidermal mild acanthosis with few rete ridges and mild papillary thinning, the inflammatory cells caused by IMQ, however, were not fully reversed and the dermis was still showing severe lymphocytic infiltrates. The ability of ivermectin to reduce the signs of IMQ-induced psoriasis could be due to its anti-inflammatory properties and ability to inhibit T cells in the skin (
In another study (
Also, TNF is a major inducer of IL-10, as reported by was highly expressed, which may explain why it is increased in the treated groups (
Ivermectin can also inhibit lipopolysaccharide (LPS)-induced production of pro-inflammatory cytokines, including TNF-a, interleukin (IL)-1b, and IL-6, mediated by NF-κB pathway suppression, which is one of the main substances in the pathogenesis of psoriasis (
All these effects of ivermectin can explain its effects on psoriasis-like skin lesions and the reduction of epidermal acanthosis, parakeratosis, and papillary thinning.
Clobetasol, on the other hand, was used as the standard treatment in this study and revealed a substantial improvement in the symptoms of psoriasis, which is explained by its anti-inflammatory and immunosuppressive actions that are linked to the development of psoriasis (
It can also modulate the T-cell response and monocytes (
In the current study, ivermectin was combined with clobetasol ointment to investigate whether this combination works better than when using either drug alone or whether it would decrease the side effects of both drugs (
One of the important roles of the used carrier is the texture that helps the medication adhere to the lesion for long periods and provides a lipid-soluble environment for treating Ivermectin, which has high lipid solubility. The effect of petrolatum was also assessed by treating ten psoriasis-induced mice with petrolatum alone, and histologically, there was no obvious improvement in psoriatic lesions. However, IL-17 and TNF-α levels decreased compared to non-treated mice; these findings indicate that petrolatum has no strong anti-psoriatic activity (
Furthermore, the histopathologic examination of the skin showed a more normal structure consisting of a keratin layer and a normal-looking Malpighian layer. It showed the absence of rete ridges& mild papillary thinning. These findings were much better than those shown when ivermectin and Clobetasol were used separately, confirming the advantages of combinational therapy mentioned earlier. However, hyperkeratosis took longer to disappear in all groups of treatment, and it may be a sign of skin healing in psoriatic lesions (
While animal models provide valuable insights into human diseases, they may not fully represent the complexity of psoriasis in humans. The study did not include clinical data from human subjects. Although the results in the mouse model are promising, further research is needed to determine the safety and efficacy of ivermectin and its combination with Clobetasol in human subjects.
Topical ivermectin possesses anti-psoriasis activity that increases IL-10 levels and could be used efficiently to alleviate psoriatic symptoms. It decreases the number of psoriatic lesions and the signs of skin inflammation in all IMQ-induced mice. The cumulative score of ivermectin plus Clobetasol was significantly better than ivermectin alone compared to the IMQ-induced group. These findings suggest that topical Ivermectin/Clobetasol has a promising effect in treating psoriasis and inflammatory skin diseases.
The “Research Ethics Committee at the College of Medicine, Al-Nahrain University” approved the study (2310, date: 1st December 2022).
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.
Underlying data:
Zenodo: “Ivermectin For Psoriasis”. https://doi.org/10.5281/zenodo.8342805 (
The project contains the following underlying data: Data set [Excell sheet]. ARRIVE guidelines 2.0: author checklist.
Data are available under the terms of the Creative Commons Attribution 4.0 International Public License (CC0 1.0 Public domain dedication).
All authors contributed to the study conception and design. [Sally Ayad Almudaris] and [Fouad Kadhim Gatea] performed material preparation, data collection, and analysis. The first draft of the manuscript was written by [Sally Ayad Almudaris], and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.